Loading
A phase 1/2 trial of Cobolimab, Dostarlimab in melanoma and hodgkin lymphoma, run by GlaxoSmithKline, active and no longer recruiting.
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer is a phase 1/2 interventional study registered as NCT06521567 by GlaxoSmithKline, with 83 participants planned, started 2025-03-06 and due to reach its primary completion in 2026-10-13. Interventions recorded: Cobolimab, Dostarlimab. Conditions listed: Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TIM-3 blockade, Cobolimab, GSK, T-cell exhaustion and CAR-T persistence.
Shares Dostarlimab, GSK, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, T-cell exhaustion and CAR-T persistence.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares TIM-3 blockade, Cobolimab.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/